Cardiovascular disease (CVD) risk can be underestimated in HIV-infected patients receiving anti-retroviral therapy (ART). Novel CVD risk markers in this population are needed. We hypothesized that eicosanoid metabolite production is increased with metabolic complications of ART. Our objective was to determine relationships between urine eicosanoids and traditional CVD risk factors in a cohort of HIV-infected persons receiving ART.
Methods
Cross-sectional analysis of 107 individuals from a prospective cohort study with urine eicosanoids (isoprostane [15-F2t-IsoP], prostaglandin-E metabolite [PGE-M], thromboxane metabolite [11dTxB2], prostacyclin metabolite [PGI-M]) determined by gas or liquid chromatography–mass spectrometry.
Results
15-F2t-IsoP was higher (P=0.003), 11dTxB2 tended to be higher (P=0.07) and PGE-M was lower (P=0.003) in females than in males. The overall median Framingham score was 4 (IQR 1–7). In multivariable analyses adjusting for age, CD4+ T-cells, smoking status, non-steroidal anti-inflammatory drug use, aspirin use and body mass index (BMI), associations included: higher 15-F2t-IsoP with female sex (P=0.004) and current smoking (P=0.04), lower PGE-M with female sex (P=0.005) and higher BMI (P=0.03), higher 11dTxB2 with increasing age (P=0.02) and current smoking (P=0.04), lower 11dTxB2 with higher BMI (P=0.02), and higher PGI-M with current smoking (P=0.04).
Conclusions
In this pilot study of predominantly virologically suppressed HIV-infected individuals on ART, there were sex-specific differences in urinary eicosanoids, with females having more risk-associated parameters despite a low Framingham score. Eicosanoids might be useful CVD biomarkers in ART-treated, HIV-infected patients. Future studies should examine eicosanoids while assessing effects of specific ART regimens and targeted interventions on CVD outcomes.
References
1.
Friis-MøllerN., ReissP., SabinC.A.Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med2007; 356: 1723–1735.
2.
LawM.G., Friis-MollerN., El-SadrW.M.The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med2006; 7: 218–230.
3.
NeuhausJ., JacobsD.R., BakerJ.V.Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis2010; 201: 1788–1795.
4.
Strategies for Management of Antiretroviral Therapy Study Group.CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med2006; 355: 2283–2296.
5.
TorrianiF.J., KomarowL., ParkerR.A.Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol2008; 52: 569–576.
6.
MorrowJ.D.Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol2005; 25: 279–286.
7.
MilneG.L., YinH., BrooksJ.D., SanchezS., Jackson RobertsL., MorrowJ.D.Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol2007; 433: 113–126.
8.
MorrowJ.D., MintonT.A.Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography–mass spectrometry. J Chromatogr1993; 612: 179–185.
9.
MurpheyL.J., WilliamsM.K., SanchezS.C.Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem2004; 334: 266–275.
10.
DanielV.C., MintonT.A., BrownN.J., NadeauJ.H., MorrowJ.D.Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography– mass spectrometry. J Chromatogr B Biomed Appl1994; 653: 117–122.
11.
SchwedhelmE., BartlingA., LenzenH.Urinary 8-iso-prostaglandin F2α as a risk marker in patients with coronary heart disease: a matched case–control study. Circulation2004; 109: 843–848.
12.
BasariciI., AltekinR.E., DemirI., YilmazH.Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis. Coron Artery Dis2007; 18: 615–620.
13.
MartinoF., LoffredoL., CarnevaleR.Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics2008; 122: e648–e655.
14.
McAdamB.F., ByrneD., MorrowJ.D., OatesJ.A.Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation2005; 112: 1024–1029.
15.
NowakJ., MurrayJ.J., OatesJ.A., FitzGeraldG.A.Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation1987; 76: 6–14.
16.
GrossN.D., BoyleJ.O., MorrowJ.D.Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res2005; 11: 6087–6093.
17.
MorrowJ.D., FreiB., LongmireA.W.Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med1995; 332: 1198–1203.
18.
CipolloneF., CicoliniG., BucciM.Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther2008; 118: 161–180.
19.
BogerM.S., ShintaniA., RedhageL.A.Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr2009; 52: 480–487.
20.
MoralesC.R., TerryE.S., ZackertW.E., MontineT.J., MorrowJ.D.Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2α)) by a stable isotope dilution mass spectrometric assay. Clin Chim Acta2001; 314: 93–99.
21.
PearsonT.A., MensahG.A., AlexanderR.W.Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003; 107: 499–511.
22.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA2001; 285: 2486–2497.
23.
DaiQ., GaoY.T., ShuX.O.Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol2009; 27: 2482–2488.
24.
WuX., CaiH., XiangY.B.Intra-person variation of urinary biomarkers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev2010; 19: 947–952.
25.
RhoY.H., ChungC.P., OeserA.Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken)2010; 62: 1473–1480.
26.
DongL.M., ShuX.O., GaoY.T.Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev2009; 18: 3075–3078.
27.
AvalosI., ChungC.P., OeserA.Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus2007; 16: 981–986.
28.
RångemarkC., BenthinG., GranstromE.F., PerssonL., WinellS., WennmalmA.Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation1992; 86: 1495–1500.
29.
WennmalmA., BenthinG., GranstromE.F., PerssonL., PeterssonA.S., WinellS.Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation1991; 83: 1698–1704.
30.
EikelboomJ.W., HirshJ., WeitzJ.I., JohnstonM., YiQ., YusufS.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation2002; 105: 1650–1655.
31.
RedhageL.A., ShintaniA., HaasD.W.Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clin Trials2009; 10: 181–192.
32.
DolanS.E., HadiganC., KillileaK.M.Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr2005; 39: 44–54.
33.
BreyerR.M., BagdassarianC.K., MyersS.A., BreyerM.D.Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol2001; 41: 661–690.
34.
DavìG., GuagnanoM.T., CiabattoniG.Platelet activation in obese women: role of inflammation and oxidant stress. JAMA2002; 288: 2008–2014.
35.
SchoenbaumE.E., HartelD., LoY.HIV infection, drug use, and onset of natural menopause. Clin Infect Dis2005; 41: 1517–1524.
36.
ManciniF., PersicoN., GenazzaniA.D., VolpeA., BattagliaC., De AloysioD.Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers. Gynecol Endocrinol2005; 20: 221–226.
37.
MueckA.O., GenazzaniA.R., SamsioeG., Vukovic-WysockiI., SeegerH.Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause2007; 14: 978–984.
38.
BayturanO., TuzcuE.M., LavoieA.The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med2010; 170: 478–484.
39.
KeaneyJ.F., LarsonM.G., VasanR.S.Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol2003; 23: 434–439.
40.
GlesbyM.J., HooverD.R., RaiszadehF.Oxidant stress in HIV-infected women from the Women's Interagency HIV Study. Antivir Ther2009; 14: 763–769.
41.
JiangB., HebertV.Y., KhandelwalA.R., StokesK.Y., DugasT.R.HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. Toxicol Lett2009; 187: 164–171.
42.
Strategies for Management of Anti-Retroviral Therapy/ INSIGHT; DAD Study Group.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS2008; 22: F17–F24.
43.
HammondE., McKinnonE., MallalS., NolanD.Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS2008; 22: 2540–2543.
44.
GerschensonM., KimC., BerzinsB.Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother2009; 63: 1244–1250.
45.
HulganT., MorrowJ., D'AquilaR.T.Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis2003; 37: 1711–1717.
46.
FlammerA.J., HermannF., WiesliP.Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens2007; 25: 785–791.
47.
PatrignaniP., Di FebboC., TacconelliS.Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Blood2006; 107: 3572–3574.
48.
Marques-VidalP., MazoyerE., BongardV.Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care2002; 25: 1371–1377.
49.
ParkK., SteffesM., LeeD.H., HimesJ.H., JacobsD.R.Association of inflammation with worsening HOMA-insulin resistance. Diabetologia2009; 52: 2337–2344.
